儿童肾移植中供体来源游离DNA的纵向评估
该研究在57例儿童肾移植受者中纵向检测供体来源游离DNA,发现移植后至少4个月内持续升高,>1%可区分活检证实的急性排斥(AUC 0.82),BK病毒尿或病毒血症期间供体来源游离DNA显著升高,>0.5%可预测随后30天eGFR更大幅度波动。
要点
- 儿童肾移植后供体来源游离DNA至少4个月内持续升高,供受体体型差异越大越明显。
- 供体来源游离DNA>1%区分活检证实的急性排斥,AUC为0.82(95%CI 0.71–0.93)。
- BK病毒尿或病毒血症期间供体来源游离DNA中位数显著升高,且同一患者内显著上升。
核心结论
- 在儿童中,供体来源游离DNA是评估移植物排斥和损伤的有价值、侵入性较小的生物标志物。
研究设计与样本
- 前瞻性生物样本库研究,连续纳入2013年1月至2019年12月在本中心接受肾移植的57例儿童,每月采集血浆,检测290份储存样本的供体来源游离DNA(AlloSure;CareDx)。
主要发现
- 儿童供体来源游离DNA水平在移植后至少4个月内持续升高,供受体体型差异越大升高越明显,之后降至稳定低水平。
- 供体来源游离DNA>1%区分活检证实的急性排斥的受试者工作特征曲线下面积为0.82(95%CI 0.71–0.93)。
- BK病毒尿或病毒血症期间,患者供体来源游离DNA中位数显著高于之前或之后,且同一患者内显著上升。
- 供体来源游离DNA>0.5%预测随后30天eGFR更大幅度波动,但不预测12个月结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Donor-derived cellfree DNA (cfDNA) is a less-invasive marker of allograft injury compared with kidney biopsy. However, donor-derived cfDNA has not yet been extensively tested in children, where the test may have different characteristics. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We assayed donor-derived cfDNA (AlloSure; CareDx) from 290 stored plasma samples from a prospective biobank at our center, collected from 57 children monthly in the first year postkidney transplant between January 2013 and December 2019. We assessed the kinetic changes in donor-derived cfDNA levels within the first year post-transplant. We analyzed donor-derived cfDNA levels for associations with biopsy-proven acute rejection using area under the receiver operating characteristic curve to longitudinal plasma and urine BK viral loads using linear mixed models. We analyzed the prognostic effect of an elevated donor-derived cfDNA level on the eGFR 30 days after the assay via Kolmogorov-Smirnov two-sample tests or on measured GFR or interstitial fibrosis at 12 months post-transplant. RESULTS: The donor-derived cfDNA levels in children remained persistently elevated for at least 4 months post-transplant, more so if there is greater disparity in size between the donor and the recipient, before reaching a steady low level. A donor-derived cfDNA level of >1% discriminated between biopsy-proven acute rejection with a receiver operating characteristic area under the curve of 0.82 (95% confidence interval, 0.71 to 0.93). During BK viruria or viremia, patients had a significantly higher median donor-derived cfDNA than before or after and a significant rise within the same patient. A donor-derived cfDNA of >0.5% predicted a wider spread in the eGFR over the next 30 days but not the 12-month outcomes. CONCLUSIONS: In children, donor-derived cfDNA is a valuable, less invasive biomarker for assessment of allograft rejection and injury. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_10_27_CJN03840322.mp3.
引用
- Dandamudi R, Gu H, Goss CW, et al. Longitudinal Evaluation of Donor-Derived Cellfree DNA in Pediatric Kidney Transplantation. Clin J Am Soc Nephrol. 2022. PMID: 36302566. doi:10.2215/CJN.03840322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。